Related Experiment Videos
Celyad's novel CAR T-cell therapy for solid malignancies
Caroline Lonez1, Alain Hendlisz2, Leila Shaza2
1Celyad, Mont-Saint-Guibert, Belgium.
Current Research in Translational Medicine
|April 8, 2018
Abstract:
Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.